Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 5, 2026Cancer Research

FGFR1+ Cancer-Associated Fibroblasts Impact CAR-T Cell Therapy in B-Cell Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

NSNicolás Di SierviMRMaría V. RevueltaGMGiovanni Medico

Discussion

Loading...

Member takes

Overview

Reveals that FGFR1+ cancer-associated fibroblasts hinder CAR T-cell efficacy in B-cell lymphoma, suggesting new treatment strategies.

Key Points

  • This research aims to understand how FGFR1+ cancer-associated fibroblasts affect CAR T-cell therapy outcomes in B-cell lymphoma.
  • Used pre-clinical lymphoma models to assess FGFR1 inhibition effects.
  • Developed patient-derived xenograft models to evaluate pharmacological FGFR1 inhibition.
  • Analyzed TGFβ secretion and changes in T-cell populations in response to treatments.
  • FGFR1 inhibition significantly decreased TGFβ levels in fibroblasts (p < 0.005).
  • Pharmacological FGFR1 inhibition increased CAR T-cell infiltration and reduced tumor burden (p < 0.005).
  • Improved overall survival was observed in combined FGFR1 inhibition and CAR T-cell therapy groups (p < 0.05).

Cite This Study

Siervi et al. (2026) studied this question.

synapsesocial.com/papers/69d1fd9ca79560c99a0a3b23https://doi.org/10.1158/1538-7445.am2026-3982
View Full Paper
Ask AI
Bookmark
Share